Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptom scores . Mean symptom scores recorded before the introduction of inhaled sodium cromoglicate and for the first eight weeks after introduction. Symptoms (22 in total) are grouped according to organ systems. Symptoms are recorded daily by patient using a 0-4 scale. Columns are mean scores for two weeks. Error bars are standard error of means. Key: solid black columns - before the introduction of inhaled sodium cromoglicate. First eight weeks after the introduction of inhaled sodium cromoglicate; solid white columns - weeks 1 and 2; columns with horizontal lines - weeks 3 and 4; columns with vertical lines - weeks 5 and 6; columns with diagonal lines - weeks 7 and 8.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptoms scores . Mean symptom scores covering a four week period commencing ten weeks after starting inhaled sodium cromoglicate treatment. Dosage of inhaled sodium cromoglicate 80 mg/day throughout. Menstrual bleed occurred during Week 3 of this four-week period. N.B. 'y' axis shows 0-3 range of 0-4 scale. Key: solid black columns - Week 1; columns with vertical lines - week 2; columns with horizontal lines - week 3; columns with diagonal lines - week 4.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: Journal of Medical Case Reports

Article Title: Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report

doi: 10.1186/1752-1947-4-193

Figure Lengend Snippet: Mean symptom scores . Mean symptom scores covering a three-week period commencing 20 weeks after starting inhaled sodium cromoglicate treatment. Menstrual bleed occurred during week 2 of this 3-week period. Dosage of inhaled SCG: 80 mg/day during week 1, 160 mg/day during week 2, 80 mg/day during week 3. N.B. 'y' axis shows 0-2 range of 0-4 scale. Key: columns with horizontal lines - week 1; columns with vertical lines - week 2; columns with diagonal lines - week 3.

Article Snippet: In this case we report how in a mastocytosis patient being treated with H 1 and H 2 antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement.

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 1 Mortality or chronic lung disease (CLD) at 28/30 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 2 Mortality to 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 3 CLD at 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 4 CLD at 36 weeks' postmenstrual age.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 5 CLD among survivors to 28 days.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 6 CLD among survivors to 36 weeks' postmenstrual age.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 7 Intraventricular haemorrhage.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 8 Necrotising enterocolitis.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 10 Air leak (pulmonary interstitial emphysema, pneumothorax).

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 11 Days on mechanical ventilation.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 12 Sepsis.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Comparison 1 Cromolyn sodium versus placebo, Outcome 9 Patent ductus arteriosus.

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Cromolyn sodium for the prevention of chronic lung disease in preterm infants

doi: 10.1002/14651858.CD003059.pub3

Figure Lengend Snippet: Cromolyn sodium versus placebo

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , Blinding of the intervention: yes. Infants received either cromolyn sodium 20 mg or 2 mL of normal saline placebo by aerosol every 6 hours while intubated. Individual drug ampoules were prepared and coded by Fisons Corp, and the code was not available to the investigators..

Techniques:

Journal: iScience

Article Title: Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

doi: 10.1016/j.isci.2021.103012

Figure Lengend Snippet: Increase in stroma associated mast cells promotes tumor growth following VNMAA treatment (A) Histological staining for collagen deposition (Picro-Sirius Red), mast cells (toluidine blue), and their co-localization (overlay) in a representative image of a tumor from a VNMAA-treated animal. Arrows point to mast cells. Scale bar represents 100 μm. (B) Bar and whisker plot of mast cell density (mast cells/mm 2 ) in PyMT-BO1 tumors from control and VNMAA-treated animals (left) and toluidine blue-stained MCs present in peripheral tumor stroma (dotted line denotes tumor margin; arrows point to mast cells; scale bar reprsents 50 μm. N = 2; n ≥ 13 animals per condition). (C) Mast cell counts in F. rodentium study. (D) Bar and whisker plot of mast cell density in EO771 tumors from control and VNMAA-treated animals (N = 2; n ≥ 7 animals per condition). (E) Bar and whisker plot of mast cell density in PyMT-BO1 tumors from control and cephalexin-treated animals (N = 1; n ≥ 5 animals per condition). (F) Bar and whisker plot of mast cell density in BRPKp110 tumors from control and VNMGA-treated animals (N = 1; n = 5 animals per condition). (G) Bar and whisker plot of mast cell density in d16HER2 tumors from control and vancomycin-treated animals (N = 1; n = 4 animals per condition). (H) Schematic of experimental timeline for mast cell inhibition experiment using cromolyn administered over the last 5 days of the experiment. (I) Bar plot of mean (±s.e.m.) endpoint tumor volumes of cromolyn-treated animals with either water or VNMAA versus control counterparts (N = 2); images below are photographs of representative whole tumors from each condition. Scale bar represents 5mm.

Article Snippet: From 10 days post tumor induction, animals received a daily intraperitoneal injection of cromolyn sodium (Merck Life Science) (10 mg/kg, 100 μL) alongside continued oral antibioitcs until experimental cessation 15 days after tumor induction.

Techniques: Staining, Whisker Assay, Inhibition

Journal: iScience

Article Title: Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth

doi: 10.1016/j.isci.2021.103012

Figure Lengend Snippet:

Article Snippet: From 10 days post tumor induction, animals received a daily intraperitoneal injection of cromolyn sodium (Merck Life Science) (10 mg/kg, 100 μL) alongside continued oral antibioitcs until experimental cessation 15 days after tumor induction.

Techniques: Recombinant, Staining, Modification, Transgenic Assay, Software

Journal: Sterile Product Development

Article Title: Considerations for the Development of Nasal Dosage Forms

doi: 10.1007/978-1-4614-7978-9_5

Figure Lengend Snippet: Commercially available locally acting nasal prescription products in the United States and EU as of December 2011 (courtesy of Lauren Seabrooks, Merck and Co., Inc.)

Article Snippet: Nasalcrom , , Cromolyn sodium , , , Spray , Prestige Brands Inc. , Allergic.

Techniques: Aerosol

Journal: Indian Journal of Ophthalmology

Article Title: Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists

doi: 10.4103/ijo.IJO_1360_22

Figure Lengend Snippet: Comparison in practice patterns between two groups: <10 years of experience versus >10 years of experience in ophthalmology practice

Article Snippet: Most preferred dose of Cromolyn sodium , 2%, BD (55%) 22/40 , 2%, BD(38.2%) 13/34 , 0.1519.

Techniques: Variant Assay

Journal: Indian Journal of Ophthalmology

Article Title: Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists

doi: 10.4103/ijo.IJO_1360_22

Figure Lengend Snippet: Survey questionnaire sent via google forms and answered by 91 respondents

Article Snippet: Most preferred dose of Cromolyn sodium , 2%, BD (55%) 22/40 , 2%, BD(38.2%) 13/34 , 0.1519.

Techniques: Injection

Journal: JOR Spine

Article Title: Characterization and modulation of the pro‐inflammatory effects of immune cells in the canine intervertebral disk

doi: 10.1002/jsp2.1333

Figure Lengend Snippet: Culture groups.

Article Snippet: In addition to no treatment controls, canine MCs were pre‐treated with 25 μM of cromolyn sodium (CS; Cayman Chemical 21 379), a mast cell stabilizer, 48 h prior to seeding with canine NP cells in 3D agarose gel (NP + MC + CS) as described above.

Techniques:

Journal: JOR Spine

Article Title: Characterization and modulation of the pro‐inflammatory effects of immune cells in the canine intervertebral disk

doi: 10.1002/jsp2.1333

Figure Lengend Snippet: (A) Effect of stiffness (1% and 4%) on gene expression of nucleus pulposus (NP) cells at 14 days and 21 days ( N = 3–6). (B) Effect of stiffness (1% and 4%) on gene expression of mast cells (MCs) at 14 days and 21 days ( N = 3–6). (C) Effect of stiffness (1% and 4%) on gene expression in the NP + MC co‐culture at 14 and 21 days ( N = 3–6). (D) Effect of stiffness (1% and 4%) on gene expression in treatment groups NP + MC + protease activated receptor 2 antagonist (PAR2A) and NP + MC + cromolyn sodium (CS) + P at 21 days ( N = 3–6). * p value <0.05, ** p value <0.005. All error bars indicate standard error mean. Statistics = linear mixed model with Benjamini–Hochberg.

Article Snippet: In addition to no treatment controls, canine MCs were pre‐treated with 25 μM of cromolyn sodium (CS; Cayman Chemical 21 379), a mast cell stabilizer, 48 h prior to seeding with canine NP cells in 3D agarose gel (NP + MC + CS) as described above.

Techniques: Gene Expression, Co-Culture Assay

Journal: JOR Spine

Article Title: Characterization and modulation of the pro‐inflammatory effects of immune cells in the canine intervertebral disk

doi: 10.1002/jsp2.1333

Figure Lengend Snippet: Effect of treatment (cromolyn sodium [CS] and/or protease activated receptor 2 antagonist [PAR2A]) on gene expression in the 4% stiffness agarose gel at 14 and 21 days ( N = 3–6). * p value <0.05. All error bars indicate standard error mean. Statistics = linear mixed model with Benjamini–Hochberg. MC, mast cell; NP, nucleus pulposus.

Article Snippet: In addition to no treatment controls, canine MCs were pre‐treated with 25 μM of cromolyn sodium (CS; Cayman Chemical 21 379), a mast cell stabilizer, 48 h prior to seeding with canine NP cells in 3D agarose gel (NP + MC + CS) as described above.

Techniques: Gene Expression, Agarose Gel Electrophoresis